United States: Implied Preemption And Monograph Drugs

Last Updated: December 13 2016
Article by James Beck

The Reed Smith blogging team has just returned from this year's annual ACI Drug & Medical Device Litigation conference. In addition to excessive amounts of eating, drinking, and socializing (now called "networking"), we kept our eyes open for new and interesting topics to blog about. We were not disappointed. We learned a lot more regarding preemption of claims involving non-prescription, over-the-counter ("OTC") drugs, particularly those governed by parts of the FDA's monograph system that we haven't considered much before.

We knew, of course, that OTC drug preemption is governed by 21 U.S.C. §379r, which contains not only an express preemption clause, but also a savings clause. Under the preemption clause, tort claims demanding warnings or other information that is "different from," "addition[al] to," or "otherwise not identical with" federal labeling requirements are preempted. However – and it's a great big however – the savings clause exempts "product liability" claims from preemption. Id. §379r(e). That doesn't mean that preemption covers nothing of interest to us. We've discussed at some length how many courts have considered non-personal injury claims to be outside the scope of the "product liability" saving language, and therefore precluded by express preemption. Most recently, we described a 2014 New Jersey case involving mouthwash that refused to apply a presumption against preemption to the express preemption clause, finding the presumption precedent "confused" and inapplicable. Bowling v. Johnson & Johnson, 65 F. Supp. 3d 371, 374 & n.17 (S.D.N.Y. 2014).

But what about implied preemption by reason of conflict – specifically the impossibility preemption rationale adopted in PLIVA, Inc. v. Mensing, 564 U.S. 604 (2011), and Mutual Pharmaceutical Co. v. Bartlett, 133 S.Ct. 2468, (2013)? What we heard at the ACI conference sounded good enough to us that we thought we'd investigate it pass along what we found.

First, we've already blogged about the recent demise of the presumption against preemption in express preemption cases. See Puerto Rico v. Franklin-California Tax-Free Trust, 136 S. Ct. 1938, 1946 (2016) ("because the statute contains an express pre-emption clause, we do not invoke any presumption against pre-emption") (citation and quotation marks omitted). While not a good thing for implied preemption generally, this difference between implied and express preemption is also a vivid demonstration of the principle that express and implied preemption operate independently. As the Supreme Court previously held in one of our favorite cases:

Respondent also suggests that we should be reluctant to find a pre-emptive conflict here because Congress included an express pre-emption provision. . . . To the extent respondent posits that anything other than our ordinary pre-emption principles apply under these circumstances, that contention must fail . . . .

Buckman Co. v. Plaintiffs' Legal Committee, 531 U.S. 341, 352 (2001). See also: Spreitsma v. Mercury Marine, 537 U.S. 51, 65, 123 S.Ct. 518, 154 L.Ed.2d 466 (2002); Geier v. American Honda Motor Co., 529 U.S. 861, 869 (2000); Freightliner v. Myrick, 514 U.S. 280, 288-289 (1995). The combination found in §379r of preemption and savings clauses do not "create some kind of 'special burden'" that would "specially disfavor pre-emption." Geier, 529 U.S. at 870.

Mensing/Bartlett preemption, of course, depends on what we call the "independence principle."

[W]hen a party cannot satisfy its state duties without the Federal Government's special permission and assistance, which is dependent on the exercise of judgment by a federal agency, that party cannot independently satisfy those state duties for pre-emption purposes.

Mensing, 564 U.S. at 623-24. Accord Bartlett, 133 S.Ct. at 2470 ("federal law prohibits generic drug manufacturers from independently changing their drugs' labels. Accordingly, state law imposed a duty on [defendant] not to comply with federal law"). That means in the OTC area, as elsewhere, there should be preemption if the defendants can't do what the plaintiffs are demanding without first going to the FDA.

First, let us point out that the rote response that "this product isn't a generic drug" is, to put it bluntly, garbage. Three Courts of Appeals have addressed this limitation, and all three have rejected it. Sikkelee v. Precision Airmotive Corp., 822 F.3d 680, 703-04 (3d Cir. 2016); Yates v. Ortho-McNeil Pharmaceuticals, Inc., 808 F.3d 281, 298 (6th Cir. 2015); In re Celexa & Lexapro Marketing & Sales Practices Litigation, 779 F.3d 34, 41 (1st Cir. 2015). Numerous trial courts cited in our drug preemption cheat sheet have held likewise. Thus there is no doctrinal obstacle to Mensing/Bartlett implied impossibility preemption applying to OTC drugs. Sikkelee, after all, involved the design of airplane parts.

So the question devolves to whether an FDA tentative monograph for an OTC drug is something that, like Wyeth v. Levine, 555 U.S. 555 (2009), can be amended at will, or is it something, like the Mensing/Bartlett line of cases, that is cannot be deviated from without prior FDA approval. The "changes being effected" regulation that the Levine court found dispositive, 21 C.F.R. §314.70, is explicitly limited to "changes to an approved NDA." Since NDAs are not required for OTC drugs subject to the monograph system, that would appear to be out.

Rather, the FDA regulations pertaining specifically to OTC products require compliance with monographs without a similar exception.

An over-the-counter (OTC) drug listed in this subchapter is generally recognized as safe and effective and is not misbranded if it meets each of the conditions contained in this part and each of the conditions contained in any applicable monograph. Any product which fails to conform to each of the conditions contained in this part and in an applicable monograph is liable to regulatory action.

21 C.F.R. §330.1 (emphasis added). Labeling/warnings are, of course, part of this process. Id. at §330.10(a)(4)(v) (addressing labeling). As long as an OTC drug complies with "any" FDA monograph applicable to it, it is not subject to "regulatory action," but if it doesn't, the FDA can go after the manufacturer. This requirement to conform strictly to the monograph specifically extends to all labeling other than the "Indications" section:

The "Uses" section of the label and labeling of the product shall contain the labeling describing the "Indications" that have been established in an applicable OTC drug monograph or alternative truthful and nonmisleading statements. . . . Any other labeling under this subchapter and subchapter C et seq. of this chapter shall be stated in the exact language where exact language has been established and identified by quotation marks in an applicable OTC drug monograph or by regulation except as provided in paragraphs (i) and (j) of this section.

Id. at §330.1(c)(2) (emphasis added). Does this regulatory "exact language" mandate sound like generic "sameness" to you? It sure does to us.

Like generics, and unlike medical devices and biologics, there is no equivalent to the CBE provisions of §314.70 in §330.1. We looked at the exceptions stated in the above block quote from §330.1(c)(2), but neither of those provisions had anything to do with strengthening labels (only use of a variety of specific, quoted language). Particularly, while a monograph is pending, and therefore "tentative," new scientific information does not support CBE-style unilateral changes to the warnings. Rather, as with generic drugs, "new" information explicitly goes to the FDA for consideration:

New data and information submitted . . . prior to the establishment of a final monograph will be considered as a petition to amend the monograph and will be considered by the Commissioner only after a final monograph has been published in the Federal Register unless the Commissioner finds that good cause has been shown that warrants earlier consideration.

Id. §330.10(a)(7)(i)(v) (emphasis added).

The FDA hasn't been able to finalize all of these monographs due to limited resources, thus a number of OTC drugs are authorized for sale under "tentative" monographs. The FDA has explained this in a guidance document for "marketed unapproved drugs":

The Agency also was faced with resource challenges because it was receiving many applications for different OTC drugs for the same indications. Therefore, in 1972, the Agency implemented a process of reviewing OTC drugs through rulemaking by therapeutic classes. . . . This process involves convening an advisory panel for each therapeutic class . . . . These panel reports are then published in the Federal Register, and, after FDA review, tentative final monographs for the classes of drugs are published. The final step is the publication of a final monograph. . . . Drugs marketed in accordance with a final monograph are considered to be generally recognized as safe and effective. . . . Final monographs have been published for the majority of OTC drugs. Tentative final monographs are in place for virtually all categories of OTC drugs.

Draft Guidance: Marketed Unapproved Drugs – Compliance Policy Guide, 2003 WL 24014273, at *8 (FDA Oct. 15, 2003) (emphasis added). These "tentative" monographs are are only tentative in that they are subject to additional formal comments. See 21 U.S.C. §330.10(7). Tentative monographs "establish[] conditions under which a category of OTC drugs or specific OTC drugs are generally recognized as safe and effective and not misbranded." Id. §330.10(7)(i).

Compliance with all tentative OTC monographs is mandatory. Another FDA regulation addresses this situation:

Marketing of such a product [an OTC drug "under consideration by an OTC advisory review panel" "on or after May 11, 1972"] with a formulation or labeling not in accord with a proposed monograph or tentative final monograph also may result in regulatory action against the product, the marketer, or both.

21 C.F.R. §330.13(b)(2) (emphasis added). By regulation, therefore, the FDA can come after any OTC drug manufacturer that violates a "proposed" or "tentative final" monograph in either the design or labeling of a drug. As to OTC drugs subject to a tentative monograph, only "marketing under [the] specified conditions will be permitted." 21 C.F.R. §330.13 (d)(2)(i); see also 21 C.F.R. §300.14(h) (for OTC products submitted after 12/23/2016).

Some OTC drugs – acetaminophen, skin protectants (sunscreen, bug repellants, lip balm, and some other stuff), and internal analgesics and related products (which previously included acetaminophen) − have been the subject of specific regulatory actions. There's a 2015 guidance for acetaminophen, for example, that indicates that the FDA is planning to issue an actual regulation to address "liver damage associated with the use of . . . OTC pediatric oral liquid acetaminophen." Over-The-Counter Pediatric Oral Liquid Drug Products Containing Acetaminophen Guidance For Industry, 2015 WL 4711458, at *1 (FDA Aug. 1, 2015). In the meantime, "[m]any of these products are marketed under the OTC conditions stated in FDA's Tentative Final Monograph for Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for OTC Human Use." Id. (footnote omitted). This 2015 guidance goes on to list a variety of "recommended" steps that manufacturers can take, but "do not establish legally enforceable responsibilities . . . and should be viewed only as recommendations." Id.

Thus these products remain "marketed under" the footnoted document, which is the 1988 "Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use; Tentative Final Monograph," 53 Fed. Reg. 46204 (FDA Nov. 16, 1988). So what is that, and can manufacturers deviate from it without getting prior FDA approval?

The 1988 tentative monograph is clear enough as to its status. It states that "the present document is designated as a 'tentative final monograph.' Its legal status, however, is that of a proposed rule." 53 Fed. Reg. at 46204. Thus, according to the FDA, "any OTC drug product subject to this monograph that is repackaged or relabeled after the effective date of the monograph must be in compliance with the monograph." Id. at 46205 (emphasis added). The FDA rejected the "conten[tion] that there is no statutory authority for the codification of exact words." Id. at 46208. "All other OTC drug labeling required by a monograph or other regulation (e.g., statement of identity, warnings, and directions) must appear in the specific wording established under the OTC drug monograph or other regulation." Id. (emphasis added). Elsewhere, the FDA spoke in terms of "requiring warning statements." Id. at 46213. It's a rather long document, but we find nothing in this tentative final monograph, published in the Federal Register, that suggests that manufacturers of OTC products subject to it are free to ignore it unilaterally. "The contents of the Federal Register shall be judicially noticed." 44 U.S.C.A. §1507.

As far as the other category, skin protectants the relevant guidance document does allow some unilateral changes, mostly to design:

Until we issue final rules for external analgesic and first aid antiseptic drug products, we do not intend to take enforcement action if an OTC drug product combines external analgesic or first aid antiseptic active ingredients identified in these tentative final monographs with applicable skin protectant active ingredients.

Draft Guidance For Industry Labeling OTC Skin Protectant Drug Products, 2008 WL 3549653, at *4 (FDA Aug. 1, 2008). As for warnings, this guidance states "[t]here are a few warnings that are required in the labeling of OTC skin protectant drug products." Id. at *6 (listing required warnings). One such product is sunscreen, and as to the the FDA has issued a final monograph. We discussed the preemptive effect of that monograph, here, and here, but all those cases were primarily express preemption and/or primary jurisdiction, the former because of the "product liability" issue we mentioned earlier.

Reviewing this material, it appears that Mensing/Bartlett preemption should apply to just about all warnings related to OTC products for which there is at least a tentative monograph. The same combination of a "sameness" requirement (the "exact language" mandate of §330.1(c)(2)) and absence of any CBE exception for "new" information (§330.10(a)(7)(i)(v)), exists for OTC products, as it does for generics. Even though denominated "tentative," the relevant documents are replete with threats of administrative action should they be deviated from during the (very long) interim period before they are to be finalized. They also use mandatory language – "must" and "required." There seems to be somewhat more leeway in the skin protection area, as described in the relevant guidance, but all the sunscreen cases so far have been fallen outside the "product liability" exception, and thus have turned on express preemption and §379(r).

Ever since the FDA began regulating OTC products, it has specifically allowed then to be regulated – and marketed – pursuant to this system of "tentative monographs" set out in 21 C.F.R. §330.10(a)(7). As described, while the FDA reserves the right to change the requirements of these monographs, in most instances the design and language of warnings therein specified cannot be unilaterally changed by regulated persons, and deviations from them are subject to FDA enforcement action. Plaintiffs may not like this system, but it is what it is. State law cannot ignore the basis on which these products have been sold for decades without putting manufacturers in an "impossible" position of being punished with liability for doing what the FDA requires them to do.

Nor, as a last resort, can state common-law posit that the tentative monograph system is a lousy system, doesn't result in "safe" products, and thus manufacturers cannot avoid liability, whether or not a particular requirement is mandatory. That would amount to telling FDA-regulated manufacturers that they cannot sell their products in accordance with the regulatory regime that the FDA has created. Such "stop selling" claims are themselves impliedly preempted:

We reject this "stop-selling" rationale as incompatible with our pre-emption jurisprudence. Our pre-emption cases presume that an actor seeking to satisfy both his federal- and state-law obligations is not required to cease acting altogether in order to avoid liability. Indeed, if the option of ceasing to act defeated a claim of impossibility, impossibility pre-emption would be "all but meaningless

Bartlett, 133 S. Ct. at 2477.

Finally, we would like to thank the drafters of this Drinker Biddle piece from 2012, in addition to the ACI material we saw the other day, for shaping our thinking in this post.

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
James Beck
Similar Articles
Relevancy Powered by MondaqAI
Reed Smith
McDermott Will & Emery
Seyfarth Shaw LLP
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Reed Smith
McDermott Will & Emery
Seyfarth Shaw LLP
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions